Early mortality in German patients with lung cancer: risk factors associated with 30-and 60-day mortality.
Bronchial tumors
Premature death
Short survival
Thoracic cancer
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
12
06
2023
accepted:
31
08
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
12
9
2023
Statut:
aheadofprint
Résumé
Despite therapeutic advances, early mortality in lung cancer is still prevalent. In this study, we aimed to assess risk factors for 30- and 60-day mortality in German lung cancer patients. In this retrospective cross-sectional analysis, we used data of lung cancer patients treated at LMU Hospital Munich between 2015 and 2019. We categorized patients into 30-day mortality, 60 day-mortality, and longer survival. We used Student's t-test and ANOVA to compare means and Chi
Identifiants
pubmed: 37700112
doi: 10.1007/s10238-023-01187-x
pii: 10.1007/s10238-023-01187-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Eisenstein M. New lung-cancer drugs extend survival times. Nature. 2020;587(7834):S10–2.
doi: 10.1038/d41586-020-03154-y
pubmed: 33208970
Temel JS, Greer JA, El-Jawahri A, et al. Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol. 2017;35(8):834–41.
doi: 10.1200/JCO.2016.70.5046
pubmed: 28029308
Amini A, Verma V, Glaser SM, et al. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019;58(8):1095–101.
doi: 10.1080/0284186X.2019.1599138
pubmed: 30958075
Burgers JA, Damhuis RA. 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? ERJ Open Res. 2018; 4(4).
Gibson AJW, Li H, D’Silva A, et al. Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: a 10 year population-based study. Lung Cancer. 2019;134:141–6.
doi: 10.1016/j.lungcan.2019.06.003
pubmed: 31319972
Grivaux M, Debieuvre D, Herman D, et al. Early mortality in lung cancer: French prospective multicentre observational study. BMC Pulm Med. 2016;16:45.
doi: 10.1186/s12890-016-0205-5
pubmed: 27039176
pmcid: 4818853
Jones GS, McKeever TM, Hubbard RB, Khakwani A, Baldwin DR. Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: an analysis of national audit data. Eur J Cancer. 2018;103:176–83.
doi: 10.1016/j.ejca.2018.07.133
pubmed: 30261439
Voigt W, Steinbock R, Scheffer B. CREDOS 3.1 ein Baukasten zur Tumordokumentation für Epidemiologische-, Klinische,-Tumorspezifische-und Zentrums-register integriert in das Kis Sap/r3 Is-h: Po344. Onkologie. 2010;33:52.
Nasseh D, Schneiderbauer S, Lange M, et al. Optimizing the analytical value of oncology-related data based on an in-memory analysis layer: development and assessment of the munich online comprehensive cancer analysis platform. J Med Internet Res. 2020;22(4): e16533.
doi: 10.2196/16533
pubmed: 32077858
pmcid: 7195671
Amini A, Glaser SM, Akhavan D, et al. Factors predicting for early mortality in non-small cell lung cancer. Int J Radiat Oncol. 2018;102(3):E670–1.
doi: 10.1016/j.ijrobp.2018.07.1813
O’Dowd EL, McKeever TM, Baldwin DR, et al. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax. 2015;70(2):161–8.
doi: 10.1136/thoraxjnl-2014-205692
pubmed: 25311471
Ampil FL, Caldito G, Devarakonda S, et al. Longevity after radiotherapy of stage III lung cancer: superior vena cava obstruction is associated with early mortality. Ann Palliat Med. 2018;7(2):242–8.
doi: 10.21037/apm.2017.10.02
pubmed: 29307206
Gorospe-Sarasúa L, Arrieta P, Muñoz-Molina GM, Almeida-Aróstegui NA. Oncologic thoracic emergencies of patients with lung cancer. Rev Clin Esp. 2019;219(1):44–50.
doi: 10.1016/j.rce.2018.06.011
pubmed: 30266451
Islam KM, Jiang X, Anggondowati T, Lin G, Ganti AK. Comorbidity and survival in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1079–85.
doi: 10.1158/1055-9965.EPI-15-0036
pubmed: 26065838
Murawski M, Walter J, Schwarzkopf L. Assessing the lung cancer comorbidome: an analysis of German claims data. Lung Cancer. 2019;127:122–9.
doi: 10.1016/j.lungcan.2018.11.030
pubmed: 30642540
Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103(6):792–802.
doi: 10.1002/ijc.10882
pubmed: 12516101
Zhu L, Cao H, Zhang T, et al. The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies. Medicine. 2016;95(17): e3528.
doi: 10.1097/MD.0000000000003528
pubmed: 27124062
pmcid: 4998725
Wei Y-F, Chen J-Y, Lee H-S, et al. Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ Open. 2018;8(1): e019661.
doi: 10.1136/bmjopen-2017-019661
pubmed: 29371286
pmcid: 5786081